Half Year 2024 Acrux Ltd Earnings Call Transcript
Key Points
- Acrux Ltd (ASX:ACR) received another FDA approval for Dapsone 5% gel, an acne treatment, in June last year.
- The company has 15 products in its portfolio, with 6 approved and 2 currently generating revenue.
- Acrux Ltd (ASX:ACR) monetized Lenzetto for EUR 4.1 million in January last year.
- The company is actively reviewing the market for additional products to add to its pipeline.
- Acrux Ltd (ASX:ACR) expects continued revenue growth from products like Prilocaine and Lidocaine cream and new products like Dapsone gel.
- The profit and loss before tax is slightly lower than last year.
- Two products that were previously generating revenue are no longer doing so.
- Supply chain issues and long lead times for components like preprinted tubes have delayed product launches.
- The company had to kill two early-stage projects in December due to economic and competitive factors.
- Market share for Prilocaine and Lidocaine has been inconsistent due to supply chain challenges.
Well, good morning, and I appreciate everyone that's joined this call. We have a number of people who have joined. My name is Michael Kotsanis. I'm the CEO of Acrux. On my left is Joanna Johnson, CFO and Company Secretary. We have a short presentation. We released this on the ASX a couple of days ago. So you're welcome to refer to any sort of slides on that. It's exactly the same presentation. And if you want to ask any questions -- we have received some prior to the call, appreciate that. But you can certainly use the Q&A function, which I see at the top of my screen and if the technology suits us, then hopefully, we can see those questions easily and I'll respond to all of them at the end of the presentation.
So thank you for joining. This is the half year results call, and we'll also go through Acrux and our progress in full. This is a disclaimer slide. We will be making some statements around our future and our forward-looking statements, so please refer to this and understand what the contents in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
